Upstate Active Clinical Trials

Study Title:

D516FC00001 - A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection (ADAURA2)

What is the purpose of the study? (in Layman's terms, please describe the study)

to learn more about whether the experimental medication osimertinib (TAGRISSOTM) is more effective than placebo in participants with EGFR mutated stage IA2 or IA3 NSCLC after complete surgical removal of the tumour.

Upstate Institutional Review Board (IRB) Number:

2024106

Study/Protocol ID:

D516FC00001- Adaura2

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Jason M Wallen, MD

Who is eligible?

18 and older

What is involved if I participate?

• How long is the study?
  3 years
• Is transportation provided or reimbursed?
  No
• Is parking provided or reimbursed?
  No
• What tests and procedures are involved?
  12-lead ECG, Echocardiogram, Ophthalmologic assessment, Blood, urine, and specimen collection for laboratory assessment,(CT) scan, and/or magnetic resonance imaging (MRI) scan, EGFR mutation (EGFRm) test, Surgical specimen collection for central pathological assessment

Where will the study take place?

SUNY Upstate Medical University

Other Information:

N/A

Who can I contact for more information?

Name: Marissa Hartley
Phone: 315-464-8232
Email: [email protected]

Return to Previous Page || Search Again